Skip to main content

Peer Review reports

From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Original Submission
25 Oct 2020 Submitted Original manuscript
25 Nov 2020 Author responded Author comments - Qianqian Wang
Resubmission - Version 2
25 Nov 2020 Submitted Manuscript version 2
4 Jan 2021 Reviewed Reviewer Report
18 Feb 2021 Reviewed Reviewer Report
21 Mar 2021 Author responded Author comments - Qianqian Wang
Resubmission - Version 3
21 Mar 2021 Submitted Manuscript version 3
24 Mar 2021 Reviewed Reviewer Report
7 Apr 2021 Reviewed Reviewer Report
19 Apr 2021 Author responded Author comments - Qianqian Wang
Resubmission - Version 4
19 Apr 2021 Submitted Manuscript version 4
23 Apr 2021 Reviewed Reviewer Report
28 Apr 2021 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
4 May 2021 Editorially accepted
25 May 2021 Article published 10.1186/s12885-021-08291-9

You can find further information about peer review here.

Back to article page